Sep 08, 2025｜2025
Henlius Showcased 9 Study Findings on Serplulimab at 2025 WCLC with 3 Oral Presentations
On September 8, 2025, Henlius (2696.HK) announced that the latest findings of nine studies on its independently developed innovative anti-PD-1 monoclonal antibody(mAb), HANSIZHUANG (serplulimab, Hetronifly® in Europe), were presented at the 2025 World Conference on Lung Cancer (WCLC), with three of the studies delivered as oral presentations. Among the highlights, the latest results from the Phase III ASTRUM-002 study—evaluating serplulimab as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC)—were presented for the first time as an oral presentation at the conference. Serplulimab is the world’s first anti-PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in nearly 40 countries and regions, including China, the UK, Germany, India, Indonesia, and Singapore, covering nearly half of the global population and accelerating global accessibility.
Henlius' self-developed innovative mAb has fully covered the first-line treatment of lung cancer. It has been approved for the treatment of squamous non-small cell lung cancer (sqNSCLC), non-squamous non-small cell lung cancer (nsqNSCLC), extensive stage small cell lung cancer (ES-SCLC), encompassing three lung cancer indications. In additon, the company is conducting a phase 3 international multi-centre clinical trial of serplulimab combined with chemotherapy and radiotherapy for limited-stage SCLC (LS-SCLC).
Due to its unique mode of recognition, serplulimab exhibits stronger PD-1 receptor endocytosis, resulting in reduction of PD-1 receptors retained on the surface of T cells[1], leading to faster and stronger immune activation effects. The results showed that, serplulimab reduced the recruitment of immune co-stimulatory receptor CD28 by PD-1, thereby decreasing the dephosphorylation of CD28 mediated by phosphatase SHP2 and retaining the signal transmitted by CD28[2-4]. Further downstream the signalling pathway, the activity of protein kinase AKT was enhanced[5], thereby promoting sustained activation of T cells.
Significantly prolongs PFS in nsqNSCLC patients, with clear benefits for brain metastasis
At this year’s WCLC, the results of the Phase 3 ASTRUM-002 study were orally presented by its leading PI, Professor Yuankai Shi of the Cancer Hospital, Chinese Academy of Medical Sciences, for the first time. The study results showed that the median progression-free survival (mPFS) of the serplulimab combined chemotherapy group reached 11.0 months, , an improvement of 5.4 months compared to chemotherapy group, with a 45% reduction in the risk of disease progression.
The brain metastasis subgroup analysis showed that adding serplulimab to chemotherapy significantly improved mPFS (8.1 months vs. 4.1 months). In the treatment group that included bevacizumab, there was still a trend of benefit in mPFS (9.7 months vs. 8.1 months). Additionally, the findings of a Phase 2 IIT study (SUPER BRAIN) on serplulimab combined with bevacizumab and chemotherapy for the first-line treatment of nsqNSCLC with brain metastasis were also delivered as mini oral presentation in the conference. The data on the four-drug combination therapy for brain metastasis further validated the efficacy of serplulimab combined with bevacizumab and chemotherapy in the brain metastasis population as demonstrated in ASTRUM-002.
Title: ASTRUM-002: First-Line Serplulimab Plus Chemotherapy With or Without HLX04 in Advanced Nonsquamous Non-small Cell Lung Cancer
Study Design: This was a three arm, randomized, double-blind, multicenter, phase 3 study. Patients with locally advanced or metastatic nsqNSCLC without EGFR sensitizing mutations or ALK/ROS rearrangements and no prior systemic therapy were randomized 1:1:1 to receive serplulimab + HX04 + chemo (group A), serplulimab +chemo (group B), or chemo (croup C). Serplulimab and HLX04 were given every 3 weeks. The primary endpoint was the BICR-assessed progression-free survival (PFS) per the REClST version 1.1. Secondary endpoints included other efficacy endpoints and safety.
Results: From November 25, 2019 to June 15, 2023 (data cutoff date), 636 patients were randomized to group A (n=212), B (n=214), or C (n=210). The median follow-up duration was 23.4 (95% CI, 21.6-24.9), 23.1 (95% Cl, 21.4-25.6), and 23.0 (95% CI, 20.7-25.6) months for the respective groups. Median PFS was significantly prolonged in group B than in group C (11.0 months vs. 5.6 months; stratified HR= 0.55, 95% CI 0.43-0.69, P < 0.0001), meeting the superiority criterion specified in the protocol. A numerical benefit in PFS was observed for group A compared to group B (12.6 months vs.11.0 months, HR=0.86, 95% CI 0.67-1.11, P=0.2529). Overall survival was not mature. Other efficacy results are listed in Table 1. Treatment-related adverse events leading to death occurred in 10 (4.7%), 5 (2.3%), and 7 (3.3%) patients in the respective groups.
Conclusion: The addition of serplulimab to chemo provided significant longer PFS compared to chemo alone in patents with locally advanced or metastatic nsqNSCLC, while the combination of serplulimab, bevacizumab and chemo provided numerical improvements in PFS when compared to serplulimab and chemo. Both treatment regimens had manageable safety profiles.
Title: Phase II Trial of Serplulimab Plus Bevacizumab and Chemotherapy for Treatment-Naive Non-Squamous NSCLC with Brain Metastases(SUPER BRAIN)
Study Design: This single-arm phase 2 clinical trial enrolled patients with advanced non-squamous NSCLC with untreated BMs that were either asymptomatic or had symptoms controlled by dehydration therapy. Patients received serplulimab combined with bevacizumab, pemetrexed, and carboplatin for four to six cycles, followed by maintenance therapy with serplulimab plus bevacizumab and pemetrexed until disease progression, unacceptable toxicity, or death, for up to two years. The primary endpoint was intracranial progression-free survival (iPFS). Intracranial outcomes were assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1.
Results: The median iPFS was 13.1, with 6-month and 12-month iPFS rates of 91.3 and 67.1% respectively. The median sPFS was 13.3 months. Nine patients (22.5%) died due to PD, and the 12-month OS rate was 71.3% . The intracranial ORR was 84.6%, with a 64.1% extracranial ORR, demonstrating potent antitumor activity.
The most common grade ≥3 TRAEs included decreased white blood cell/neutrophil count, reduced platelet count, and abnormal liver function. No treatment-related deaths were reported.
Conclusion: Serplulimab plus bevacizumab and chemotherapy demonstrated promising intracerebral antitumor efficacy and a manageable safety profile for patients with non-squamous NSCLC with BMs in the first-line setting.
Full Coverage of LC first-line treatment, exploring therapeutic potential in a broader population
At the same time, several IIT study findings on serplulimab-based immunotherapies were also selected for multiple sessions, including oral presentations, poster tours, and poster presentations. These studies explored the therapeutic potential of immunotherapy in a wide range of populations, such as EGFR-TKI-Resistant or perioperative NSCLC lung cancer patients, and confirmed the efficacy of serplulimab in more sub-groups of ES-SCLC patients.
Title: Bevacizumab Plus Serplulimab and Chemotherapy for EGFR-TKI-Resistant Non-squamous Non-small-cell Lung Cancer: A Phase 2 Study
Results: This is a multicenter, single-arm phase 2 trial. 46 patients from nine centers across China were enrolled (aged 18-70 years with EGFRmut nsq-NSCLC, ECOG PS 0-1, documented disease progression after first- to third-generation EGFR-TKI therapy (≤2 lines), and no history of immunochemotherapy exposure). Eligible patients receive 4-6 cycles of HLX04 (7.5 mg/kg, day 1) plus HLX10 (300 mg, day 1), in combination with standard chemotherapy consisting of pemetrexed and carboplatin every 3 weeks, followed by maintenance therapy with HLX04 plus HLX10 and pemetrexed until progression, unacceptable toxicity, or up to 2 years (35 cycles). This study enrolled . The ORR was 47.8% (95% CI: 32.9-63.0%), achieving the predefined target of 45.0%. The median TTR and DoR were 1.5 months (95% CI: 1.4 - 2.8) and 6.2 months (95% CI: 5.3 - NR), respectively. Patients without brain metastases were more likely to achieve better efficacy (ORR: 52.4% vs. 44.0%; median PFS: 9.5 vs. 7.1 months). PFS showed no significant differences across prior therapy lines or EGFR-TKI regimen. The median TTR and DoR were 1.5 months (95% CI: 1.4 - 2.8) and 6.2 months (95% CI: 5.3 - NR), respectively. The incidence of any grade of AEs was 80.4% (37/46), and 17 patients (37.0%) had grade ≥3 AEs.
Conclusion: These findings indicated that a dose-reduced bevacizumab regimen combined with serplulimab and platinum-based doublet chemotherapy exhibited promising efficacy and manageable safety for patients with EGFR-TKI-resistant nsq-NSCLC.
Title: Serplulimab in Neoadjuvant Therapy for Locally Advanced Non-Small Cell Lung Cancer: A Prospective Single-Arm Study
Results: This is a prospective, single-arm clinical study which enrolled 55 patients with stage II-IIIB (T4N2) NSCLC based on the AJCC 8th edition, whose tumors are assessed as resectable or potentially resectable. Patients received 3 cycles of neoadjuvant therapy consisting of serplulimab (300 mg) combined with chemotherapy. Radiographic assessment showed complete response (CR) in 2 patients. Partial response (PR) in 38 (90.5%), and stable disease (SD) in 2 (4.8%). The ORR was 95.2% (40/42). 87.5%(35/40) patients underwent thorascopic resection. The R0 resection rate was 100%. The MPR rate was 67.5% (27/40), and the pcr rate was 37.5% (15/40). 20 patients (36.4%, 20/55) experienced AEs, including 5 patients (9.1%, 5/55) with grade ≥3 AEs. 6 patients discontinued treatment due to AEs, but no surgical was delayed due to treatment-related toxicity. 1 patient developed a serious perioperative complication (bronchopleural fistula), which resolved after stent placement and conservative management.
Conclusion: Interim results suggest that serplulimab in combination with chemotherapy demonstrates promising efficacy and manageable safety as neoadjuvant therapy for patients with locally advanced NSCLC. These findings warrant confirmation with continued patient enrollment and longer follow-up.
Title: Multi-Cycle Low-Dose Radiotherapy Reshapes lmmunochemotherapy forES-SCLC: The SPUR Phase II Trial
Results: This is a Phase II, single-arm, multicenter study designed to evaluate the safety and efficacy of LDRT-concurrent cisplatin/carboplatin plus etoposide with Serplulimab in participants who have ES-SCLC and are chemotherapy-naïve for their extensive-stage disease. At data cut-off (July 31, 2025), the median follow-up was 17.9 months (range: 0.8-27.2). The confirmed objective response rate (ORR) was 84.8% (50/59; 95%CI: 73.0-92.8%), and DCR was 88.1% (52/59; 95% CI: 77.1-95.1%); The median DoR was 7.7 months (95% CI: 4.1-11.0). The median PFS was 7.3 months (95%CI: 5.9 – 11.6), with a 6-month PFS rate of 61.1% (95% CI: 50.0 – 74.9%), and 12-month PFS rate of 31.5% (95% CI: 21.5-46.0%). Patients without liver metastases experienced significantly longer PFS than those with liver metastases (median PFS: 10.7 vs. 4.4 months; log-rank P = 0.002). The OS data was not mature yet.
Conclusion: This study demonstrated a promising survival benefit and manageable toxicity of first-line serplulimab and chemotherapy combined with multi-cycle LDRT in ES-SCLC. Twelve patients (19.7%) are still on treatment, long-term and exploratory analysis results are warranted.
Title: First-Line Immunochemotherapy in ES-SCLC Patients with ECOG PS ≥2: Real-World Evidence from the ASTRUM-005R Trial
Results: ASTRUM-005R is a nationwide, real-world, observational study conducted in China to assess the safety and effectiveness of first-line serplulimab-based immunochemotherapy in patients with ES-SCLC. This subgroup analysis focused on patients with ECOG PS ≥2 to explore the feasibility and clinical outcomes in this population. A total of 75 patients with ECOG PS ≥2 were included in this analysis, accounting for 11.8% of the overall ASTRUM-005R cohort. Among them, 71 patients had PS 2 and 4 had PS 3. The median follow-up duration was 16.37 months (range, 1.90-23.60). Compared to patients with PS <2, poor performance status did not significantly affect rwPFS (HR = 1.15, P = 0.366). The median rwPFS for patients with PS ≥2 was 6.97 months (95% CI, 6.23-10.43), with a 1-year rwPFS rate of 26.62% (95% CI, 17.22-41.14). Similar to the overall cohort, baseline brain metastases had no significant impact on rwPFS (HR = 0.98, P = 0.953). However, patients with liver metastases had significantly shorter rwPFS than those without (4.93 vs. 10.30 months; HR = 1.95, P = 0.018). OS was poorer in patients with PS ≥2 compared to those with PS <2 (HR = 1.89, P < 0.001), with a median OS of 12.33 months (95% CI, 10.43-15.57). Again, brain metastases had no significant effect on OS (HR = 0.86, P = 0.640), while liver metastases were associated with inferior OS (9.67 vs. 14.03 months; HR = 3.01, P = 0.001). Among 74 patients with measurable disease and at least one post-treatment radiological evaluation, the ORR was 66.22% (95% CI, 54.28-76.81). Safety profiles in patients with ECOG PS ≥2 were generally consistent with those observed in the overall population. Adverse events (AEs) were reported in 20 patients (26.67%), and 15 patients experienced immune-related adverse events (irAEs), with 5 reporting grade ≥3 irAEs.
Conclusion: Our findings suggest that baseline ECOG PS at diagnosis does not significantly impact long-term prognosis in ES-SCLC patients, and those with ECOG PS ≥2 can also derive substantial survival benefits from first-line immunochemotherapy. However, most of the included studies were retrospective real-world studies, necessitating cautious interpretation of the results. Further large-scale prospective trials incorporating patients with poor ECOG PS are warranted to comprehensively assess the efficacy and safety of first-line immunochemotherapy in this population.
Title: Meta-Analysis of First-Line Immunochemotherapy in ES-SCLC: Does ECOG PS ≥2 Affect Survival Outcomes?
Results: This meta-analysis evaluates the survival benefits of first-line immunochemotherapy in ES-SCLC patients with ECOG PS ≥2. The pooled analysis estimated that 20.02% (95% CI 14.39-26.29) of newly diagnosed ES-SCLC patients had ECOG PS ≥2. Meta-analysis results demonstrated that ECOG PS did not significantly impact survival outcomes following first-line treatment. Compared to patients with ECOG PS <2, those with ECOG PS ≥2 exhibited no significant difference in OS (HR = 1.14, 95% CI: 0.80-1.63) or PFS (HR = 1.19, 95% CI: 0.88-1.62). Subgroup analysis further revealed that among patients receiving first-line immunochemotherapy, OS (HR = 1.25, 95% CI: 0.77-2.03) and PFS (HR = 1.10, 95% CI: 0.78-1.54) did not differ significantly between ECOG PS ≥2 and PS <2 subgroups. Notably, in the ECOG PS ≥2 subgroup, immunochemotherapy conferred a significant survival advantage compared to chemotherapy alone, with an OS HR of 0.64 (95% CI: 0.47-0.87) and a PFS HR of 0.44 (95% CI: 0.28-0.68), indicating both short- and long-term survival benefits.
Conclusion: Our findings suggest that baseline ECOG PS at diagnosis does not significantly impact long-term prognosis in ES-SCLC patients, and those with ECOG PS ≥2 can also derive substantial survival benefits from first-line immunochemotherapy. However, most of the included studies were retrospective real-world studies, necessitating cautious interpretation of the results. Further large-scale prospective trials incorporating patients with poor ECOG PS are warranted to comprehensively assess the efficacy and safety of first-line immunochemotherapy in this population."
Title: Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive-Stage Small Cell Lung Cancer
Results: This study prospectively enrolled previously untreated ES-SCLC patients. All patients received 6 cycles of standard chemotherapy combined with serplulimab, followed by serplulimab monotherapy maintenance. Plasma ctDNA samples were collected at multiple time points, including the baseline, after 2 and 6 cycles of chemo-immunotherapy, at 6 months post-chemotherapy cessation, and upon tumor progression. The MRD status was identified by a next-generation sequencing panel covering 2365 lung cancer-relevant genes with an average sequencing depth of approximately 30000×. Kaplan-Meier curves and log-rank tests were performed in survival analyses. A comparison of the top 30 genes in tissue and plasma. Most genes detected in tissue (21/30) were also detectable in plasma, demonstrating a high degree of consistency between the two sample types. ORR：100% DCR：100% （13/13). Persistent MRD+group PFS 6.26m；MRD clearance group PFS NA，P = 0.043；
Conclusion: tDNA-based MRD detection represents a promising biomarker for predicting prognosis in ES-SCLC. MRD clearance during treatment predicts better PFS. ctDNA monitoring is more sensitive than conventional imaging for detecting progression, identifying molecular signs of disease progression months earlier. These preliminary findings, based on a small cohort, highlight the need for further validation with expanded data.
【Reference】
[1] Issafras H, et al. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy. PLoS One. 2021;16(12):e0257972.
[2] Hui E, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428-1433.
[3] Patsoukis N, et al. Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Commun Biol. 2020;3(1):128.
[4] Fenwick C, et al. Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway. J Exp Med. 2019;216(7):1525-1541.
[5] Primavera E, et al. Computer-Aided Identification of Kinase-Targeted Small Molecules for Cancer: A Review on AKT Protein. Pharmaceuticals (Basel). 2023;16(7):993.
Back
Privacy Policy
Cookies Policy
Accessibility
Terms of Use
Privacy Policy
Introduction
Shanghai Henlius Biotech, Inc., and, where applicable, its affiliates and subsidiaries (collectively, “we” , “us” or “our”) attach great importance to the protection of your privacy and personal information. This Privacy Notice (this “Policy”) is formulated in accordance with applicable PRC laws and regulations governing the protection of personal information in the People’s Republic of China (“PRC”).
This Policy applies when: (1) you browse or use our website and other online resources (such as our WeChat official accounts); (2) subscribe to our news or announcements; or (3) contact us through the contact details or other interactive features made available on our website, or otherwise interact with us through our website.. The purpose of this Policy is to explain how and why we process your personal information, the types of personal information involved, applicable retention periods, your rights, and the measures we take to protect personal information. Please read this Policy carefully to ensure that you fully understand its content.
In certain business scenarios, we may provide additional explanations regarding the processing of your personal information through separate agreements, privacy statements, or personal information notices. In the event of any inconsistency, such documents shall prevail. For example, where a recruitment function is provided through a third-party platform or service, the relevant third party privacy policy or notice may also apply.
For the purposes of this Policy, “personal information” refers to all kinds of information related to identified or identifiable natural persons, excluding anonymized information.
We collect, use, store, transfer and otherwise process personal information in strict compliance with applicable PRC laws and regulations of the People’s Republic of China.
Our website may contain links to third party websites for your convenience. We do not control, and are not responsible for, the privacy practices of such third parties. We encourage you to review their privacy policies before using those websites.
If you have any questions or concerns regarding this Policy or our processing of personal information, please contact us using the details provided below.
This Policy will help you understand:
I. How we collect your personal information
II. How we use your personal information
III. How we entrust, share, transfer and publicly disclose your personal information
IV. Cross border transfer of personal information
V. How we store your personal information
VI. Security measures
VII. Your rights
VIII. Personal information of minors
IX. Updates to this Policy
X. How to contact us
I. How do we collect your personal information?
In addition to our employees, we may process personal information of the following persons:
• Visitors and users of our website;
• Healthcare Professionals;
• Investigators of clinical trial institutions and personnel of contract research organizations in clinical trials;
• Subjects of clinical trials and their relatives;
• Consumers/patients and their relatives using our products or services;
• Staff of business partners (including vendors, distributors, partners, etc.); and
• Our applicants.
We may process personal information of website visitors and individuals who contact or interact with us through our website or other online resources. Depending on the relevant page, function, or interaction, separate privacy notices, consents, platform privacy policies, contracts, or other notices may apply.
Based on the context in which you interact with us, we may collect personal information by the following means and on the legal bases permitted by applicable PRC laws and regulations, including your consent, the necessity for entering into or performing a contract, compliance with legal obligations, protection of life, health or property, public health needs, or other circumstances permitted by law:
• Your personal information provided to us voluntarily
When you subscribe to our news or announcements, contact us through the contact details or other interactive features made available on our website, a third-party platform or service linked or referred to on our website, or otherwise communicate with us in relation to our website, we may collect the personal information that you voluntarily provide, such as your name, contact details, organization, and the content of your inquiry or request, depending on the relevant page or function.
• Personal information collected by us independently through our website and other online channels
When you visit our website, most of our services do not require any registration, and you can visit our website without telling us who you are. However, some pages or functions may require you to provide certain personal information. If you choose not provide such information as we request, you may not be able to access certain content or functions or we may not be able to respond to your inquiry, request or subscription. Please refer to the relevant page or notice for further details about the categories of personal information collected in a specific scenario.
• Personal information we collect from vendors or business partners
In the course of our daily business operations, we may collect personal information from our vendors or business partners. We require our vendors and business partners to comply with the requirements of the personal information protection laws and regulations of the PRC and to lawfully provide us with personal information. If you are an employee or representative of one of our vendors or business partners, we may collect personal information such as your name and contact details for the purpose of establishing business contacts and cooperations.
• Personal information we collect from publicly available sources
We may collect personal information of medical and healthcare professionals from such publicy available sources, such as the official websites of medical institutions and the official websites of competent government departments, and process such information within a reasonable scope and for lawful purposes. For example, for the purpose of lawful academic or professional interaction with healthcare professionals, we may collect the name, gender, employer, position, practitioner registration information, academic title, degree, educational background, specialty expertise, and profile information, where such information has been lawfully made public.
Our website may include links, contact details, QR codes, or references to third-party platforms or services. Where you choose to interact with us through such third-party platforms or services, the relevant third party may also process your personal information in accordance with its own privacy policy and applicable law, and we encourage you to review such policy before submitting your information.
II. How do we use your personal information?
We may use your personal information for the following purposes:
• Operating, maintaining and improving our website and other online resource;
• Researching, developing, providing and continuously improving our products and services;
• Conducting and managing daily business;
• Academic interaction with healthcare professionals;
• Responding to your inquiries, requests, or communications sent through our website or the contact details made available on our website;
• Providing subscription services for our news, announcements, or investor-related updates;
• Managing and maintaining our relationship and communications with business contacts who reach us through our website;
• Recruiting and human resource management;
• Internal compliance management，audit，record-keeping; and
• Complying with applicable PRC laws and regulations, for example, monitoring and reporting adverse events for purposes of performing drug quality management responsibilities, providing medical information and dealing with product complaints, etc..
We will process personal information only to the extent necessary for the relevant purpose. Where required by applicable law, we will obtain your consent or separate consent before processing your personal information or sensitive personal information. Where a third-party platform or service is used in connection with a particular function, the relevant third party may process your personal information in accordance with its own privacy policy and applicable law.
III. How do we entrust, share, transfer and publicly disclose your personal information?
1. Entrustment
We may entrust our business partners with the processing of your personal information for the purpose(s) described in this Policy. We will enter into appropriate confidentiality, data processing and security agreements with such entrusted parties and require them to process personal information in accordance with our instructions , this Policy and applicable PRC laws and regulations.
2. Sharing and public disclosure
For the purpose(s) described in this Policy, we will share or publicly disclose your personal information only where permitted by applicable PRC laws and regulations and, where required, after obtaining your consent or separate consent. Such circumstances may include:
• Sharing your personal information among our affiliates and subsidiaries where necessary for legitimate business, management, compliance, or operational purposes;
• Sharing your personal information with vendors or business partners (such as conference service providers, travel service providers, data service providers, banking or insurance institutions, other professional service organizations, to the extent necessary for the relevant purpose); and
• Disclosing your personal information to the extent that it is permitted or required by applicable PRC laws and regulations or for the purpose of assisting with investigations by judicial, regulatory or law enforcement authorities.
• other circumstances permitted by applicable PRC laws and regulations.
If you submit your information through or in connection with a third-party platform or service referred to on our website, the relevant third party may independently process your personal information in accordance with its own privacy policy and applicable law.
3. Transfer
We will not transfer your personal information to any other company, entity or individual unless otherwise permitted by applicable law and, where required, after obtaining your consent. Further, in the event of a merger, acquisition, insolvency, reorganization, division, dissolution, bankruptcy, or similar transaction, we will require the new processor of your personal information to continue to be bound by this Policy or we will require the new processor to obtain your consent again.
IV.How do we provide your personal information across borders?
In principle, personal information that we collect and generate in the course of our operations within the territory of the PRC will be stored within the PRC. In certain circumstances, it may be necessary for us to provide your personal information to recipients outside the PRC in connection with our business operations, website functions, or communications, where permitted by applicable PRC laws and regulations. As required by applicable laws and regulations regarding the protection of personal information, we will provide you with the required notice and obtain your separate consent before providing your personal information across any border, unless otherwise permitted by law. We will use lawful cross-border transfer mechanisms to transfer your personal information oversea and will take necessary measures to ensure that the oversea recipients provide a level of protection required by applicable PRC laws and regulations.
You may obtain more information about cross-border transfers of personal information and oversea recipients through the contact methods referred to in this Policy.
V. How do we store your personal information?
We will retain your personal information for the minimum period necessary to achieve the purposes described in this Policy ,unless a longer retention period is required or permitted by applicable PRC laws and regulations. Upon expiration of the applicable retention period, we will promptly delete or anonymize your personal information in accordance with applicable PRC laws and regulations. Our criteria for determining the period for which personal information shall be retained include:
• Applicable laws, regulations and other relevant requirements;
• The period of time needed for us to provide services, maintain business relations or interact with you; and
• The period of time needed for us to perform relevant agreements or fulfil the purposes described in this Policy.
VI. What security measures do we take to protect your personal information?
In accordance with applicable PRC laws, regulations, and the requirements of relevant national standards, we take reasonable and appropriate security and precautionary measures to protect the personal information we process against unauthorized access, public disclosure, use, modification, destruction or loss of data. However, you are also responsible for taking appropriate measures to protect the security of the devices, systems, and networks you use when accessing our website or communicating with us.
VII. Your rights
In accordance with the requirements of the applicable PRC laws and regulations, you may have the following rights in respect of your personal information:
• To know about and make decisions regarding the processing of your personal information;
• To access or copy your personal information;
• To correct or supplement your personal information;
• To delete your personal information;
• To request for explanation of rules regarding processing of personal information; and
• To change the scope of your consent or revoke your consent , where processing is based on your consent.
If you wish to exercise your rights with respect to personal information, you may contact us through the contact information listed in this Policy and we will respond to any request in accordance with applicable relevant laws and regulations. When you exercise the above rights, we may verify your identity to safeguard the security of your personal information. Subject to applicable PRC laws and regulations, there may be circumstances where we are unable to respond to all or part of your request.
VIII. How do we process the personal information of minors?
For the purposes of this Policy and in accordance with applicable PRC laws and regulations, our products, websites and services are not targeted at minors under the age of 14. Minors under the age of 14 should not provide personal information to us without the consent of a parent or legal guardian.
If a minor's personal information is collected with the consent of a parent or legal guardian, we will process the information only when permitted by law, with the express consent of the parent or legal guardian, or necessary for the protection of the minor. If we discover that we have collected personal information without obtaining verifiable prior consent of a parent or legal guardian, we will seek to delete the data as soon as possible.
IX. Updates of the Policy
We may revise our Privacy Policy from time to time. We will post the updated version on our website and update the “Last Updated” date above or below this Policy.
Last updated: March 30, 2026.
X. How to contact us?
If you have any questions, comments or suggestions concerning this Policy, or any questions or concerns about our processing of your personal information, you may contact us in the following ways:
Address: 11/F, B8 Building, No.188 Yizhou Rd, Xuhui District, Shanghai
Tel.: 021- 33395800
Postal Code: 200233
Email: PR@lshhqj.com
Cookies Policy
When you visit our website, we may place small data files known as “cookies” on your device. Cookies enable our website to recognize your browser and help us understand how visitors use the site.
Cookies and similar technologies used on this website may collect online identifiers, device information, browser information, IP address, and information about how you interact with the website. In certain circumstances, such information may constitute personal information or may be associated with you under applicable PRC laws and regulations. Information collected through cookies is used for purposes such as ensuring website operation, maintaining security, analyzing traffic and performance, remembering user preferences, and improving website content and user experience.
You may choose to accept or decline cookies by adjusting your browser settings or through any cookie banner or preference center made available on our website, if applicable. Please note that disabling cookies may affect the functionality of certain parts of the website.
For more information about how we process personal information, please refer to our Privacy Notice.
Some cookies may be provided by third parties. Where third-party cookies or similar technologies are used, such third parties may process the relevant information in accordance with their own privacy policies and applicable PRC laws and regulations.
Accessibility
Shanghai Henlius Biotech, Inc. (“Henlius”) is committed to improving the accessibility and user friendliness of its website for all visitors.
We strive to ensure that the content on our website can be accessed and used by individuals with diverse needs, including those who rely on assistive technologies. As our website continues to evolve, we recognize that accessibility is an ongoing effort, and we are continuously working to improve usability and accessibility across our digital platforms.
If you experience difficulty accessing any part of our website, or have suggestions on how we can enhance accessibility, we welcome your feedback. To help us respond effectively, please include the specific webpage address (URL) and a brief description of the issue encountered.
Contact us:
Email: PR@lshhqj.com
(Please include “Website Accessibility” in the subject line)
Henlius will make reasonable efforts to review accessibility-related feedback and improve the overall online experience for all users. While we strive to improve accessibility, we do not guarantee that every page or feature will be fully accessible to every user in all circumstances.
Terms of Use
This website (http://www.lshhqj.com/) is developed and operated by Shanghai Henlius Biotech, Inc. (“Henlius”). Please read these Terms of Use carefully before accessing or using this website. By accessing, browsing or using this website, you acknowledge that you have read, understood and agreed to be bound by these Terms of Use and applicable PRC laws and regulations.
Henlius reserves the right to modify or update these Terms of Use at any time. Any updated version will be posted on this website with a revised “Last Updated” date. Please review them periodically for updates.
Prohibited Conduct:
You shall not infringe the lawful rights and interests of Henlius or any third party, nor interfere with or attempt to interfere with the normal operation, security, or integrity of this website by any means. Without limitation, you shall not use this website for any unlawful purpose, attempt unauthorized access to any part of the website or related systems, introduce malicious code, scrape or extract website content through automated means, or otherwise interfere with the website’s operation or security features.
Copyright
All content on this website, including but not limited to text, data, logos, graphics, audio, video and other materials, is owned by Henlius or its respective rights holders, unless otherwise stated. Such content is protected by applicable Chinese and international copyright laws. This website and its content may be accessed and used only for lawful, personal, and non-commercial purposes. Without prior written consent, no entity or individual may copy, reproduce, republish, upload, post, transmit, distribute, modify, create derivative works from, mirror, or otherwise use such content for commercial or public purposes.
Disclaimers
To the fullest extent permitted by applicable PRC laws and regulations, Henlius makes no warranties or representations, express or implied, regarding the content of this website, including but not limited to accuracy, completeness, timeliness or suitability for any particular purpose. Henlius does not undertake any obligation to update the content of this website , except as otherwise required by applicable PRC laws and regulations.
You use this website and any information obtained from it at your own risk. To the fullest extent permitted by applicable PRC laws and regulations, Henlius shall not be liable for any loss or damage arising from the use or inability to use this website, including but not limited to system failures, computer viruses or data loss.
Medical Information
Nothing on this website constitutes medical advice, diagnosisor treatment recommendations. Medical decisions should always be made in consultation with qualified healthcare professionals. Any product-related or disease-related information provided on this website is provided for general informational purposes only and should not be construed as medical advice, diagnosis, or treatment recommendations; any product information is subject to the approved prescribing information and applicable local laws and regulations.
Third Party Websites
This website may contain links to third party websites for convenience. Henlius is not responsible for the content, availability, privacy practices, terms or use of such third-party websites. Access to third party websites is at your own risk.
Privacy
Henlius respects your privacy. Please refer to our Privacy Notice for details.
Governing Law
These Terms of Use shall be governed by the laws of the People’s Republic of China.
Last updated: March 30, 2026